Navigation Links
Orexigen(R) Therapeutics to Present at Upcoming Meetings
Date:5/13/2009

SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the following meetings:

    BIO 2009 Business Forum
    Date:  Tuesday, May 19, 2009
    Time:  9:20 a.m. - 9:35 a.m. Eastern
    Location:  Georgia World Congress Center, Room 316, Atlanta, Georgia
    Speaker:  Dr. Dennis Kim, Senior Vice President, Medical Affairs and
              Communications

    Eighth Annual JMP Securities Research Conference
    Date:  Tuesday, May 19, 2009
    Time:  9:00 a.m. - 9:30 a.m. Pacific
    Location:  The Ritz Carlton, San Francisco
    Speaker:  Graham Cooper, Chief Financial Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
2. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
3. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
4. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
5. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
6. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
9. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
10. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
11. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , ... January 19, 2017 , ... ... product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, is ... fully 21 CFR Part 11-compliant email client designed to provide product vigilance departments ...
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical Informatics Association ... Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans ... policy. AMIA recommended that NIH earmark funding for researchers to produce and execute ...
(Date:1/19/2017)... ... , ... FireflySci Inc. is a go-getter type of company that continues to ... two main factors. The first is the amazing customer service that the FireflySci ... all around the world. , 2016 was a tremendous sales year for FFS and ...
Breaking Biology Technology:
(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):